Zelnorm most-recalled DTC TV ad, Plavix most motivating

Share this article:

Novartis' DTC television ad for Zelnorm was the most recalled by consumers, while Sanofi-Aventis' 60-second spot for Plavix was the most motivating, according to the latest data from IAG Research, a TV effectiveness ratings company.
According to the rankings data, in the five months ending Aug. 31, 2005, 31 new prescription drug ads across 21 brands, both new and existing, aired on prime-time TV across all broadcast and major cable television networks.
Of the new ads, adults 18 and older most often recalled the latest TV ad for Zelnorm as a treatment for irritable bowel syndrome. A black-and- white film-noir spoof ad for Glaxo-SmithKline's Flonase followed at No. 2.
Sepracor's Lunesta, which launched in April 2005, also scored high in the recall category, ranking fourth out of the top five recalled ads.
In addition to tracking 24-hour recall for brands, the IAG's findings included rankings for ads that were the most successful at motivating viewers who recall them to speak with their doctors about the promoted brand.
Sanofi-Aventis' latest 60-second ad for its cardiovascular drug Plavix encouraged the highest level of "stated intent to take action" among adults 18 and older, relative to the average for all new prescription drug ads launched during the study period. AstraZeneca followed at No. 2  with a 45-second spot for Nexium for the treatment of acid indigestion/reflux.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.